Taiwan Biomaterial (6649) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 台生材

Taiwan Biomaterial (6649) reported revenue of NT$12.4 million for Oct 2026, -34.1% year on year and -27.4% from the previous month. Revenue for Jan–Oct 2026 was NT$119.5 million (-38.1% year on year).

In Oct 2026, it ranked No. 131 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$9.7 million24/10Nov 2024 NT$8.9 millionDec 2024 NT$10.4 millionJan 2025 NT$15.8 millionFeb 2025 NT$33.2 million25/02Mar 2025 NT$18.7 millionApr 2025 NT$8.8 millionMay 2025 NT$13.7 millionJun 2025 NT$11.3 million25/06Jul 2025 NT$17.8 millionAug 2025 NT$21.5 millionSep 2025 NT$33.5 millionOct 2025 NT$18.8 million25/10Nov 2025 NT$10.6 millionDec 2025 NT$16.9 millionJan 2026 NT$7.7 millionFeb 2026 NT$7.2 million26/02Mar 2026 NT$11.5 millionApr 2026 NT$11.5 millionMay 2026 NT$12.3 millionJun 2026 NT$13.1 million26/06Jul 2026 NT$12.4 millionAug 2026 NT$14.4 millionSep 2026 NT$17 millionOct 2026 NT$12.4 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$12.4 million-34.1%-27.4%
Sep 2026NT$17 million-49.3%+18.0%
Aug 2026NT$14.4 million-32.8%+16.4%
Jul 2026NT$12.4 million-30.3%-5.8%
Jun 2026NT$13.1 million+16.5%+6.9%
May 2026NT$12.3 million-9.9%+7.0%
Apr 2026NT$11.5 million+29.9%-0.3%
Mar 2026NT$11.5 million-38.2%+60.0%
Feb 2026NT$7.2 million-78.3%-5.9%
Jan 2026NT$7.7 million-51.5%-54.5%
Dec 2025NT$16.9 million+61.5%+59.0%
Nov 2025NT$10.6 million+18.8%-43.5%
Oct 2025NT$18.8 million+93.0%-44.1%
Sep 2025NT$33.5 million+435.7%+56.2%
Aug 2025NT$21.5 million+77.2%+20.9%
Jul 2025NT$17.8 million+95.0%+57.4%
Jun 2025NT$11.3 million+96.0%-17.4%
May 2025NT$13.7 million+44.0%+54.3%
Apr 2025NT$8.8 million+45.4%-52.6%
Mar 2025NT$18.7 million+220.7%-43.7%
Feb 2025NT$33.2 million+534.1%+110.0%
Jan 2025NT$15.8 million+106.9%+51.4%
Dec 2024NT$10.4 million+124.7%+16.9%
Nov 2024NT$8.9 million-11.6%-8.2%
Oct 2024NT$9.7 million+546.3%+55.2%

Jan–Oct 2026 cumulative: NT$119.5 million (-38.1% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Taiwan Biomaterial vs PEC / Taiwan Biomaterial vs Lotus Pharm / Taiwan Biomaterial vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16